Suppr超能文献

与年龄相关和与疾病相关的肌肉损失:糖尿病、肥胖症和其他疾病的影响。

Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases.

机构信息

Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, The Johns Hopkins University, Baltimore, MD, USA.

Clinical Research Branch, National Institute on Aging, Baltimore, MD, USA.

出版信息

Lancet Diabetes Endocrinol. 2014 Oct;2(10):819-29. doi: 10.1016/S2213-8587(14)70034-8. Epub 2014 Mar 6.

Abstract

The term sarcopenia refers to the loss of muscle mass that occurs with ageing. On the basis of study results showing that muscle mass is only moderately related to functional outcomes, international working groups have proposed that loss of muscle strength or physical function should also be included in the definition. Irrespective of how sarcopenia is defined, both low muscle mass and poor muscle strength are clearly highly prevalent and important risk factors for disability and potentially mortality in individuals as they age. Many chronic diseases, in addition to ageing, could also accelerate decrease of muscle mass and strength, and this effect could be a main underlying mechanism by which chronic diseases cause physical disability. In this Review, we address both age-related and disease-related muscle loss, with a focus on diabetes and obesity but including other disease states, and potential common mechanisms and treatments. Development of treatments for age-related and disease-related muscle loss might improve active life expectancy in older people, and lead to substantial health-care savings and improved quality of life.

摘要

肌肉减少症是指随着年龄增长而发生的肌肉质量损失。基于研究结果表明肌肉质量与功能结果仅有中度相关性,国际工作组提出肌肉力量或身体功能的丧失也应包含在定义中。无论如何定义肌肉减少症,肌肉质量低和肌肉力量差在个体衰老时显然是高度普遍且重要的残疾和潜在死亡风险因素。除了衰老之外,许多慢性疾病也可能加速肌肉质量和力量的下降,这种影响可能是慢性疾病导致身体残疾的主要潜在机制。在这篇综述中,我们既关注与年龄相关的肌肉减少,也关注与疾病相关的肌肉减少,重点关注糖尿病和肥胖症,但也包括其他疾病状态,以及潜在的共同机制和治疗方法。针对与年龄相关和与疾病相关的肌肉减少症的治疗方法的发展可能会提高老年人的活跃预期寿命,并带来大量的医疗保健节省和提高生活质量。

相似文献

1
Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases.
Lancet Diabetes Endocrinol. 2014 Oct;2(10):819-29. doi: 10.1016/S2213-8587(14)70034-8. Epub 2014 Mar 6.
2
An Overview of Sarcopenic Obesity.
J Clin Densitom. 2015 Oct-Dec;18(4):499-505. doi: 10.1016/j.jocd.2015.04.013. Epub 2015 Jul 2.
4
Sarcopenic obesity in ageing: cardiovascular outcomes and mortality.
Br J Nutr. 2020 Nov 28;124(10):1102-1113. doi: 10.1017/S0007114520002172. Epub 2020 Jun 18.
5
Muscle loss and obesity: the health implications of sarcopenia and sarcopenic obesity.
Proc Nutr Soc. 2015 Nov;74(4):405-12. doi: 10.1017/S002966511500169X. Epub 2015 Apr 27.
6
Obesity, sarcopenia and their functional consequences in old age.
Proc Nutr Soc. 2011 Feb;70(1):114-8. doi: 10.1017/S0029665110003939. Epub 2010 Nov 22.
7
Sarcopenia: a predictor of mortality and the need for early diagnosis and intervention.
Aging Clin Exp Res. 2015 Jun;27(3):249-54. doi: 10.1007/s40520-014-0281-4. Epub 2014 Nov 4.
9
Sarcopenic obesity, weight loss, and mortality: the English Longitudinal Study of Ageing.
Am J Clin Nutr. 2017 Jul;106(1):125-129. doi: 10.3945/ajcn.117.152488. Epub 2017 May 24.
10

引用本文的文献

2
Prevention of Sarcopenia.
Adv Exp Med Biol. 2025;1478:365-405. doi: 10.1007/978-3-031-88361-3_15.
4
Comparison of sarcopenia screening indices using serum creatinine and cystatin C in metabolic dysfunction-associated steatotic liver disease.
Front Med (Lausanne). 2025 Aug 7;12:1633837. doi: 10.3389/fmed.2025.1633837. eCollection 2025.
6
Estimated glucose disposal rate and non-HDL-c/HDL-c ratio with the progression of carotid atherosclerosis: a long-term cohort study.
Front Med (Lausanne). 2025 Jul 17;12:1627246. doi: 10.3389/fmed.2025.1627246. eCollection 2025.
7
9
Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study.
Drug Des Devel Ther. 2025 Jul 3;19:5645-5652. doi: 10.2147/DDDT.S531778. eCollection 2025.
10
Editorial: Purinergic signaling in metabolic diseases and inflammation pharmacology.
Front Pharmacol. 2025 Jun 19;16:1631388. doi: 10.3389/fphar.2025.1631388. eCollection 2025.

本文引用的文献

2
Muscle wasting in collagen-induced arthritis and disuse atrophy.
Exp Biol Med (Maywood). 2013 Dec;238(12):1421-30. doi: 10.1177/1535370213505961. Epub 2013 Nov 1.
3
Prevalence and clinical correlates of sarcopenia in community-dwelling older people: application of the EWGSOP definition and diagnostic algorithm.
J Gerontol A Biol Sci Med Sci. 2014 Apr;69(4):438-46. doi: 10.1093/gerona/glt149. Epub 2013 Oct 1.
4
Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment.
Indian J Endocrinol Metab. 2013 Sep;17(5):913-6. doi: 10.4103/2230-8210.117215.
5
Interaction between bone and muscle in older persons with mobility limitations.
Curr Pharm Des. 2014;20(19):3178-97. doi: 10.2174/13816128113196660690.
6
Effect of physical exercise on muscle mass and strength in cancer patients during treatment--a systematic review.
Crit Rev Oncol Hematol. 2013 Dec;88(3):573-93. doi: 10.1016/j.critrevonc.2013.07.001. Epub 2013 Aug 9.
7
Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials.
Int J Biochem Cell Biol. 2013 Oct;45(10):2288-301. doi: 10.1016/j.biocel.2013.06.024. Epub 2013 Jul 8.
8
Sarcopenic obesity in aging population: current status and future directions for research.
Endocrine. 2014 Feb;45(1):15-25. doi: 10.1007/s12020-013-9992-0. Epub 2013 Jul 3.
9
Abnormal protein turnover and anabolic resistance to exercise in sarcopenic obesity.
FASEB J. 2013 Oct;27(10):3905-16. doi: 10.1096/fj.12-224006. Epub 2013 Jun 26.
10
Lifestyle interventions and independence for elders study: recruitment and baseline characteristics.
J Gerontol A Biol Sci Med Sci. 2013 Dec;68(12):1549-58. doi: 10.1093/gerona/glt064. Epub 2013 May 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验